Lipid Controls
Avanti Polar Lipids 18 1-D7 LYSO PC
18 1-d7 Lyso PC1-oleoyld7-2-hydroxy-sn-glycero-3-phosphocholine1mg
Cayman Chemical DLin-KC2-DMA, Purity: ≥98%, CAS: 1190197-97-7, 5 mg
An ionizable cationic lipid (pKa = 6.7); has been used in the formation of LNPs encapsulating siRNA or plasmid DNA for use in vitro and in vivo; LNPs containing DLin-KC2-DMA selectively accumulate in the liver after i.v. or i.m. administration in mice or localize to the retinal pigment epithelium and Müller glia after subretinal administration; DLin-KC2-DMA-containing LNPs encapsulating F7-targeted siRNA reduce serum Factor VII levels in mice; DLin-KC2-DMA-containing LNPs encapsulating AR-targeted siRNA decrease serum PSA and tumor androgen receptor levels in an LNCaP prostate cancer mouse xenograft model
Avanti Polar Lipids 16:0-18:1 PG (25MG)
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt). 268550-95-4
Avanti Polar Lipids EGG PCC 95% L-A-PHOSPHATIDYLCH
L- alpha -Phosphatidylcholine, 95% (Egg, Chicken). 97281-44-2
Avanti Polar Lipids 17 1 LYSO PS 5MG
1- /10Z-heptadecenoyl/-2-hydroxy-sn-glycero-3- /phospho-L-serine/ sodium salt
Avanti Polar Lipids 4ME 16:0 (DPHPC), 200 MG
1,2-diphytanoyl-sn-glycero-3-phosphocholine. 207131-40-6
Apexbio Technology LLC DMG-PEG2000-NH2-MW-2000-25MG
DMG-PEG2000-NH (MW 2000) is a polyethylene glycol (PEG) derivative frequently used in biomedical research as a drug delivery vehicle and stabilizing agent Originating from its ability to enhance the solubility and bioavailability of therapeutic compounds it operates by attaching to drug molecules or nanoparticles forming a protective hydrophilic layer that can improve circulation time and distribution in biological systems The polymer exhibits effective activity in the nanomolar to low micromolar range commonly employed in various in vitro and in vivo studies including cell models and animal research It plays a crucial role in drug screening processes where enhanced delivery and distribution are required Typical applications involve examining its effects within specific cellular pathways and evaluating pharmacokinetic profiles Experimental concentrations typically depend on the specific research design